Glomerulonephritis - Pipeline Review, H1 2017

Published: Apr, 2017 | Pages: 137 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H1 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine), foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glomerulonephritis - Overview
Glomerulonephritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Glomerulonephritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glomerulonephritis - Companies Involved in Therapeutics Development
Achillion Pharmaceuticals Inc
Alexion Pharmaceuticals Inc
Anthera Pharmaceuticals Inc
Biogen Inc
BLR Bio LLC
ChemoCentryx Inc
Dimerix Bioscience Pty Ltd
GlaxoSmithKline Plc
Mallinckrodt Plc
Omeros Corp
Pfizer Inc
Pharmalink AB
Ra Pharmaceuticals Inc
Retrophin Inc
Rigel Pharmaceuticals Inc
Shire Plc
Visterra Inc
Glomerulonephritis - Drug Profiles
(irbesartan + propagermanium) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ACH-4471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AMY-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVX-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxB-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BaxG-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
blisibimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLR-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCX-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fostamatinib disodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
losmapimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-1355 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rituximab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Factor D for PNH and Dense Deposit Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor D for Paroxysmal Nocturnal Hemoglobinuria and Membranoproliferative Glomerulonephritis Type II - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sparsentan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-5484 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VAR-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-649 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Glomerulonephritis - Dormant Projects
Glomerulonephritis - Discontinued Products
Glomerulonephritis - Product Development Milestones
Featured News & Press Releases
Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update
Feb 28, 2017: Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program CCX140
Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board
Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy
Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Glomerulonephritis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Glomerulonephritis - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
Glomerulonephritis - Pipeline by Biogen Inc, H1 2017
Glomerulonephritis - Pipeline by BLR Bio LLC, H1 2017
Glomerulonephritis - Pipeline by ChemoCentryx Inc, H1 2017
Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H1 2017
Glomerulonephritis - Pipeline by Mallinckrodt Plc, H1 2017
Glomerulonephritis - Pipeline by Omeros Corp, H1 2017
Glomerulonephritis - Pipeline by Pfizer Inc, H1 2017
Glomerulonephritis - Pipeline by Pharmalink AB, H1 2017
Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
Glomerulonephritis - Pipeline by Retrophin Inc, H1 2017
Glomerulonephritis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
Glomerulonephritis - Pipeline by Shire Plc, H1 2017
Glomerulonephritis - Pipeline by Visterra Inc, H1 2017
Glomerulonephritis - Dormant Projects, H1 2017
Glomerulonephritis - Discontinued Products, H1 2017